By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Oncology. According to news reporting from Frankfurt, Germany, by NewsRx journalists, research stated, "Nanoparticles (NP) as carriers for anti-cancer drugs have shown great promise. Specific targeting of NP to malignant cells, however, remains an unsolved problem."
The news correspondents obtained a quote from the research from the University of Frankfurt, "Conjugation of antibodies specific for tumor membrane antigens to NP represents one approach to improve specificity and to increase therapeutic efficacy. In the present study, for the first time a novel membrane heat shock protein (Hsp70)-specific antibody (cmHsp70.1) was coupled to human serum albumin (HSA) NP, loaded with microRNA (miRNA) plasmids to target the inhibitor of apoptosis protein survivin. The physicochemical properties of monodisperse miRNA-loaded NP showed a diameter of 180 nm to 220 nm, a plasmid incorporation of more than 95% and a surface binding capacity of the antibody of 70-80%. Antibody-conjugated NP displayed an increased cellular uptake in U87MG and LN229 glioblastoma cells compared to isotype control antibody, PEG-coupled controls and peripheral blood lymphocytes (PBL). Survivin expression was significantly reduced in cells treated with the Hsp70-miRNA-NP as compared to non-conjugated NP. Hsp70-miRNA-NP enhanced radiation-induced increase in caspase 3/7 activity and decrease in clonogenic cell survival."
According to the news reporters, the research concluded: "In summary, cmHsp70.1 miRNA-NP comprise an enhanced tumor cell uptake and increased therapeutic efficacy of radiation therapy in vitro and provide the basis for the development of antibody-based advanced carrier systems for a tumor cell specific targeting."
For more information on this research see: Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells. Journal of Controlled Release, 2013;172(1):201-6. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news journalists report that additional information may be obtained by contacting S. Gaca, Dept. of Pharmaceutical Technology, University of Frankfurt, Max-von-Laue-Str 9, 60438 Frankfurt am Main, Germany. Additional authors for this research include S. Reichert, G. Multhoff, M. Wacker, S. Hehlgans, C. Botzler, M. Gehrmann, C. Rodel, J. Kreuter and F. Rodel (see also Oncology).
Keywords for this news article include: Antibodies, Europe, Germany, Oncology, Frankfurt, Immunology, Glioblastoma, Nanoparticle, Therapeutics, Blood Proteins, Nanotechnology, Immunoglobulins, Radiation Therapy, Emerging Technologies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC